Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Respiratory virus panels for global surveillance of emerging infectious diseases

Gary T. Bricea,*, Steven J. Drewsb, Donald E. Lowc

aDepartment of Immunology, United States Naval Medical Research Unit #2, FPO AP 96520–8132, USA
bMolecular Diagnostics, Ontario Public Health Laboratories, Ministry of Health and Long Term Care, Toronto, Ontario, Canada
cMicrobiology, Mount Sinai Hospital, Toronto, Ontario, Canada

Keywords: Diagnostic assays; Multiplex; Infectious Disease Surveillance

1. Introduction

The success in dealing with SARS can partially be attributed to detection of a unique disease within an established healthcare system, international efforts to contain the spread of disease, and rapid identification of a newly emerging pathogen using advanced molecular techniques. Despite this success, the outbreak exposed several weaknesses in the established surveillance networks and demonstrated the potential social and economic toll infectious disease outbreaks can exert, even in developed countries. SARS was a slow-spreading virus with low communicability and a long incubation period, yet it spread to 29 countries in five continents over a period of a few weeks, infecting over 8000 patients with 774 fatalities (Poon et al., 2004). In contrast, influenza has a shorter incubation period, higher infectiousness rate than SARS and annually kills tens of thousands of persons. Global attention is now focused on the increasing number of influenza A H5N1 outbreaks in poultry and humans, as well as increased infections of humans with other avian influenza viruses (Wong and Yuen, 2006). Although no clear evidence of efficient human-to-human transmission of avian influenza has as yet been reported, the increased number of confirmed influenza A H5N1 in family clusters raises concerns that sustained human-to-human transmission will soon emerge (Gilsdorf et al., 2006; Kandun et al., 2006).

The SARS epidemic in 2002, Streptococcus suis outbreaks in China in 2005 (Ye et al., 2006), and the current spread of influenza A H5N1 around the world are examples that highlight the need for global engagement on regional disease outbreaks, especially in resource-poor countries where the burden of disease is highest (Lopez et al., 2006). Sustained global investment is needed to improve the capacity in many developing countries to detect endemic, epidemic and newly emerging pathogens. Accurate determination of agent-specific regional disease burden will help guide the allocation of limited resources for use in existing prevention modalities, provide crucial information for vaccine development, and assist public health authorities to establish directed vaccination programs and other public health prevention strategies. Since agent-specific disease burden estimates will likely vary based on regional conditions, it is important to establish the different geographic and epidemiological profiles in order to establish priorities for prevention strategies.

2. Dilemmas in identifying viral pathogens in respiratory samples

Public health laboratories (PHLs), which form the foundation of the global surveillance network, are faced with some key dilemmas with respect to the identification of viral pathogens in respiratory samples. We believe that many of these problems might be addressed through the selective use of some of the newly available commercial respiratory viral panels (RVPs). The newest of these RVPs allows for the sensitive and specific detection of viral pathogens following extensive multiplexing of polymerase chain reaction (PCR) and reverse-transcriptase PCR (RT-PCR) reactions without the loss of sensitivity previously seen in other diagnostics systems (Li et al., 2007).

2.1. Dilemma 1 – How to deal with large numbers of patient samples?

During SARS our laboratory in Toronto faced surges of numbers in respiratory samples that were 5–10 times those normally encountered. During a normal respiratory virus
season our PHL will also be required to identify a wide variety of respiratory viruses in tens of thousands of patient samples from respiratory virus outbreaks as well as sporadic cases of fever and respiratory illness. Thus, identification methods must be rapid, comprehensive and must conserve laboratory as well as human resources (Brown, 2006; Cheng et al., 2004). Although traditional methods of identification that use a combination of methods (i.e. culture, rapid antigen detection assays and low target number molecular assays) are often effective (Dunn et al., 2004; Zitterkopf et al., 2006) the combination of these techniques reduces the number of patient samples that can be tested at any one time, and also limits the sample volume available for further testing (Khanna et al., 2005).

2.2. Dilemma 2 – How to be a comprehensive reference laboratory?

Since the etiology of one-half to three-quarters of community-acquired pneumonia cases is unknown, new technologies to identify a wider variety of respiratory viruses are needed (Ewig et al., 2002; Fine et al., 1999; Garbino et al., 2002). The initial difficulties of culturing emerging avian influenza viruses (Brown, 2006) and common viruses such as human metapneumovirus (Scheltinga et al., 2005) indicate that PHLs must develop culture-independent diagnostic methods. Even though non-culture based methods (i.e. molecular diagnostics) are widely available for the identification of individual respiratory viral pathogens, methods for simultaneously screening for a wide array of pathogens are needed (Rachlin et al., 2005).

2.3. Dilemma 3 – How to prepare for emerging respiratory pathogens including pandemic influenza and bioterrorism agents?

The past decade has seen the emergence of several new respiratory viruses (Gillim-Ross and Subbarao, 2006). The spectre of these agents, including pandemic influenza and bioterrorism agents, means that PHLs will face increasing pressure to identify new agents as they emerge, and develop a capacity to separate highly pathogenic agents from less virulent seasonal respiratory viruses (Cirino et al., 2004). Extensively multiplexed PCR reactions may help PHLs identify a wide variety of agents without the use of Biosafety Level III laboratories. Molecular techniques will also allow PHLs to identify subtypes and strains of emerging respiratory viruses, and laboratory working groups for pandemic influenza now suggest that PHLs retain the ability to subtype and characterize influenza strains (i.e. resistance testing and virulence testing) using these techniques1.

3. Commercial respiratory virus panels as a solution to these dilemmas

We propose that the above dilemmas might be solved through the use of broad-spectrum commercially available respiratory virus panels which utilize extensively multiplex technologies. With proper planning, RVPs may be integrated into protocols that allow for large numbers of samples to be tested rapidly and economically (Brunstein and Thomas, 2006). The inclusion of “difficult to grow” viral pathogens in these panels will provide better data on their prevalence. RVPs can also be integrated into pandemic preparedness and bio-terrorism plans. Not only can they be used for the sub-typing of influenza viruses but they may be used during the early phases of a pandemic to differentiate between outbreaks caused by seasonal influenza or other pathogens and those caused by an emerging pandemic strain. The extensively multiplexed nature of newer RVPs might allow for the development of new tools for the diagnosis of pathogens used in biological warfare and bioterrorism.

4. Conclusions

We believe that the emergence of commercially available respiratory virus panels heralds a new era in public health microbiology. These tools will hopefully not only improve work flow but will also benefit clinical reporting, public health epidemiology and increase laboratory preparedness for pandemic influenza and other emerging pathogens.

5. Conflict of interest statement

None declared.

6. Acknowledgements

Dr. Brice would like to thank Jean-Paul Chretien and Shannon Putnam for their discussions and review of the manuscript. The opinions are the views of the author, and are not to be construed as official views of the Department of the Navy or the Department of Defense. Dr. Low’s research is supported by Tm BioScience.

References

Brown IH. Advances in molecular diagnostics for avian influenza. Dev Biol (Basel) 2006;124:93−7.
Brunstein J, Thomas E. Direct screening of clinical specimens for multiple respiratory pathogens using the Genaco Respiratory Panels 1 and 2. Diagn Mol Pathol 2006;15:169−73.
Cheng SM, Vainionpaa R, Zhao P, Li F, Hu A, Forrest B, et al. Detection of influenza B in clinical specimens: comparison of high throughput RT-PCR and culture confirmation. Virus Res 2004;103:85−90.

1 http://www.phac-aspc.gc.ca/cpih-pclipi/ann-c_e.html
Cirino NM, Musser KA, Egan C. Multiplex diagnostic platforms for detection of biothreat agents. Expert Rev Mol Diagn 2004;4:841–57.
Dunn JJ, Woolstenhulme RD, Langer J, Carroll KC. Sensitivity of respiratory virus culture when screening with R-mix fresh cells. J Clin Microbiol 2004;42:79–82.
Ewig S, Torres A, Angeles Marcos M, Angrill J, Rano A, de Roux A, et al. Factors associated with unknown aetiology in patients with community-acquired pneumonia. Eur Respir J 2002;20:1254–62.
Ewig S, Torres A, Angeles Marcos M, Angrill J, Rano A, de Roux A, et al. Factors associated with unknown aetiology in patients with community-acquired pneumonia. Eur Respir J 2002;20:1254–62.
Fine MJ, Stone RA, Singer DE, Coley CM, Marrie TJ, Lave JR, et al. Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study. Arch Intern Med 1999;159:970–80.
Garbin J, Sommer R, Gerber A, Regamey C, Vernazza P, Genne D, et al. Prospective epidemiologic survey of patients with community-acquired pneumonia requiring hospitalization in Switzerland. Int J Infect Dis 2002;6:288–93.
Gillim-Ross L, Subbarao K. Emerging respiratory viruses: challenges and vaccine strategies. Clin Microbiol Rev 2006;19:614–36.
Gilsdorf A, Boxall N, Gasimov V, Agayev I, Mammadzade F, Ursu P, et al. Two clusters of human infection with influenza A/H5N1 virus in the Republic of Azerbaijan, February–March 2006. Eur Surveill 2006;11:122–6.
Kandun IN, Wibisono H, Sedyaningsih ER, Yusharmen, Hadisoedarsuno W, Purba W, et al. Three Indonesian clusters of H5N1 virus infection in 2005. N Engl J Med 2006;355:2186–94.
Khanna M, Fan J, Pehler-Harrington K, Waters C, Douglass P, Stalock J, et al. The pneumoplex assays, a multiplex PCR-enzyme hybridization assay that allows simultaneous detection of five organisms, Mycoplasma pneumoniae, Chlamydia (Chlamydophila) pneumoniae, Legionella pneumophila, Legionella micdadei, and Bordetella pertussis, and its real-time counterpart. J Clin Microbiol 2005;43:565–71.
Li H, McCollom MA, Estes RW, Sefers SE, Daren RD, Chappell JD, et al. Simultaneous detection and high-throughput identification of a panel of RNA viruses causing respiratory tract infections. J Clin Microbiol 2007;45:2105–9.
Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006;367:1747–57.
Poon LL, Guan Y, Nicholls J, Yuen KY, Peiris JS. The aetiology, origins, and diagnosis of severe acute respiratory syndrome. Lancet Infect Dis 2004;4:663–71.
Rachlin J, Ding C, Cantor C, Kasif S. MuPlex: multi-objective multiplex PCR assay design. Nucleic Acids Res 2005;33:W544–7.
Scheltinga SA, Templeton KE, Beersma MF, Claas EC. Diagnosis of human metapneumovirus and rhinovirus in patients with respiratory tract infections by an internally controlled multiplex real-time RNA PCR. J Clin Virol 2005;33:306–11.
Wong SS, Yuen KY. Avian influenza virus infections in humans. Chest 2006;129:156–68.
Ye C, Zhu X, Jing H, Du H, Segura M, Zheng H, et al. Streptococcus suis sequence type 7 outbreak, Sichuan, China. Emerg Infect Dis 2006;12:1203–8.
Zitterkopf NL, Leekha S, Espy MJ, Wood CM, Sampathkumar P, Smith TF. Relevance of influenza A virus detection by PCR, shell vial assay, and tube cell culture to rapid reporting procedures. J Clin Microbiol 2006;44:3366–7.